191 related articles for article (PubMed ID: 16788334)
1. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.
Lam S; See S
Cardiol Rev; 2006; 14(4):205-11. PubMed ID: 16788334
[TBL] [Abstract][Full Text] [Related]
2. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
3. Exenatide: a new option for the treatment of type 2 diabetes.
Yoo BK; Triller DM; Yoo DJ
Ann Pharmacother; 2006 Oct; 40(10):1777-84. PubMed ID: 16985091
[TBL] [Abstract][Full Text] [Related]
4. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
Gallwitz B
Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
[TBL] [Abstract][Full Text] [Related]
5. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
[TBL] [Abstract][Full Text] [Related]
6. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
Sheffield CA; Kane MP; Busch RS
Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
[TBL] [Abstract][Full Text] [Related]
7. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
8. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
9. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
10. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
11. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
Iltz JL; Baker DE; Setter SM; Keith Campbell R
Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088
[TBL] [Abstract][Full Text] [Related]
12. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
[TBL] [Abstract][Full Text] [Related]
13. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
Paisley AN; Savage MW; Wiles PG
Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
[TBL] [Abstract][Full Text] [Related]
14. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
[TBL] [Abstract][Full Text] [Related]
15. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Fabreegas B
Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
[No Abstract] [Full Text] [Related]
16. Exenatide. From the Gila monster to you. Exenatide is the first of a new class of drugs known as "incretin mimetics" that can enhance your blood glucose control.
Clark WL
Diabetes Self Manag; 2006; 23(1):36, 39-40. PubMed ID: 16453919
[No Abstract] [Full Text] [Related]
17. Incretins and their role in the management of diabetes.
Frias JP; Edelman SV
Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
[TBL] [Abstract][Full Text] [Related]
18. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
Reuter H; Erdmann E
Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
[TBL] [Abstract][Full Text] [Related]
19. Exenatide for the treatment of type 2 diabetes mellitus.
Ruddock B
Issues Emerg Health Technol; 2005 Aug; (71):1-4. PubMed ID: 16389694
[TBL] [Abstract][Full Text] [Related]
20. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
Parkes DG; Mace KF; Trautmann ME
Expert Opin Drug Discov; 2013 Feb; 8(2):219-44. PubMed ID: 23231438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]